Astellas gets Japan marketing OK for prostate cancer drug
TOKYO, June 29
TOKYO, June 29 (Reuters) - Astellas Pharma Inc said on Friday it had received approval to market prostate cancer treatment drug Gonax in Japan.
Gonax, which controls the growth of prostate cancer by suppressing testosterone production, has been approved in 59 countries, the company said in a statement. (Reporting by Chang-Ran Kim; Editing by Michael Watson)